Pharmacology and the Nursing
Process
10th Edition
• Author(s)Linda Lane Lilley;
Shelly Rainforth Collins; Julie
S. Snyder
TEST BANK
,QUESTION 1
Item Type: MCQ
Clinical Scenario:
A 68-year-old female patient with hypertension and type 2
diabetes mellitus is prescribed a newly FDA-approved
antihypertensive medication. The patient asks the nurse, "I
heard this drug was just approved last month. How do I know
it's safe for me to take?"
Question Stem:
What is the most appropriate response by the nurse regarding
the FDA drug approval process?
Answer Options:
A. "The FDA requires extensive post-marketing surveillance to
identify adverse effects not seen in clinical trials."
B. "New drugs are approved only after being tested in
thousands of patients over 10-15 years."
C. "You should wait at least one year after FDA approval before
starting any new medication."
D. "The FDA approval process guarantees the drug is completely
safe for all patients."
Correct Answer: A
Comprehensive Rationale:
The FDA's drug approval process involves multiple phases of
,clinical trials (Phase I, II, and III) before a New Drug Application
(NDA) is submitted and reviewed. However, even after approval,
drugs undergo Phase IV post-marketing surveillance to monitor
for adverse effects that may not have been detected in pre-
approval trials due to limited sample sizes, short duration, or
narrow patient populations. This surveillance includes
MedWatch reporting, adverse event reporting systems, and
ongoing studies that may identify rare or long-term adverse
effects. The nurse's response should provide accurate
information while acknowledging the ongoing monitoring
process that ensures continued safety evaluation.
Distractor Analysis:
B: "New drugs are approved only after being tested in
thousands of patients over 10-15 years."
• Why Incorrect: This overstates both the timeline and
sample size. While drug development can take 10-15 years
from discovery to approval, clinical trials typically involve
thousands, not hundreds of thousands, of patients. The
statement implies a false level of certainty about safety.
• Common Clinical Misconception: Patients often believe
that FDA approval represents complete safety and that all
adverse effects are known at the time of approval.
, • Medication Safety Risk: This misconception may lead
patients to believe that post-marketing adverse effects do
not occur, potentially delaying reporting of adverse events.
• Appropriate Nursing Action: Nurses should provide
accurate information about the drug approval process
while emphasizing the importance of reporting any
unusual symptoms.
C: "You should wait at least one year after FDA approval
before starting any new medication."
• Why Incorrect: This is not evidence-based practice.
Delaying necessary medication therapy based on arbitrary
timelines may compromise patient outcomes. Many
patients benefit from new medications that offer
advantages over existing therapies.
• Common Clinical Misconception: Patients may believe
that all new drugs are inherently dangerous and should be
avoided.
• Medication Safety Risk: Unnecessary delay in appropriate
pharmacotherapy may result in preventable morbidity or
mortality.
• Appropriate Nursing Action: The nurse should engage in
shared decision-making, discussing both benefits and risks
Process
10th Edition
• Author(s)Linda Lane Lilley;
Shelly Rainforth Collins; Julie
S. Snyder
TEST BANK
,QUESTION 1
Item Type: MCQ
Clinical Scenario:
A 68-year-old female patient with hypertension and type 2
diabetes mellitus is prescribed a newly FDA-approved
antihypertensive medication. The patient asks the nurse, "I
heard this drug was just approved last month. How do I know
it's safe for me to take?"
Question Stem:
What is the most appropriate response by the nurse regarding
the FDA drug approval process?
Answer Options:
A. "The FDA requires extensive post-marketing surveillance to
identify adverse effects not seen in clinical trials."
B. "New drugs are approved only after being tested in
thousands of patients over 10-15 years."
C. "You should wait at least one year after FDA approval before
starting any new medication."
D. "The FDA approval process guarantees the drug is completely
safe for all patients."
Correct Answer: A
Comprehensive Rationale:
The FDA's drug approval process involves multiple phases of
,clinical trials (Phase I, II, and III) before a New Drug Application
(NDA) is submitted and reviewed. However, even after approval,
drugs undergo Phase IV post-marketing surveillance to monitor
for adverse effects that may not have been detected in pre-
approval trials due to limited sample sizes, short duration, or
narrow patient populations. This surveillance includes
MedWatch reporting, adverse event reporting systems, and
ongoing studies that may identify rare or long-term adverse
effects. The nurse's response should provide accurate
information while acknowledging the ongoing monitoring
process that ensures continued safety evaluation.
Distractor Analysis:
B: "New drugs are approved only after being tested in
thousands of patients over 10-15 years."
• Why Incorrect: This overstates both the timeline and
sample size. While drug development can take 10-15 years
from discovery to approval, clinical trials typically involve
thousands, not hundreds of thousands, of patients. The
statement implies a false level of certainty about safety.
• Common Clinical Misconception: Patients often believe
that FDA approval represents complete safety and that all
adverse effects are known at the time of approval.
, • Medication Safety Risk: This misconception may lead
patients to believe that post-marketing adverse effects do
not occur, potentially delaying reporting of adverse events.
• Appropriate Nursing Action: Nurses should provide
accurate information about the drug approval process
while emphasizing the importance of reporting any
unusual symptoms.
C: "You should wait at least one year after FDA approval
before starting any new medication."
• Why Incorrect: This is not evidence-based practice.
Delaying necessary medication therapy based on arbitrary
timelines may compromise patient outcomes. Many
patients benefit from new medications that offer
advantages over existing therapies.
• Common Clinical Misconception: Patients may believe
that all new drugs are inherently dangerous and should be
avoided.
• Medication Safety Risk: Unnecessary delay in appropriate
pharmacotherapy may result in preventable morbidity or
mortality.
• Appropriate Nursing Action: The nurse should engage in
shared decision-making, discussing both benefits and risks
